

CURRICULUM VITAE

Name Arata Azuma, MD, PhD
Title Professor
Birth date June 15, 1957
Birthplace Tokyo, Japan
Citizenship Japanese
Marital Status Married, two children(daughters)

Education 1983: Graduated from Nippon Medical School
1983-88: Resident (Pulmonary medicine, Clinical oncology)
1989-91: Research work (Department of Immunology, Juntendo University)
1991-: MD, PhD, Nippon Medical School, Tokyo, Japan

Academic Career

1994 – present Secretary General of the ‘Research Group on Novel Effects of Macrolides’
1996 – present Assistant Professor of Pulmonary Medicine, Nippon Medical School
1996 – present Councilor of the Japan Association of Sarcoidosis and Other Granulomatous Diseases
1999 – present Member of a research group of the Ministry of Health, Welfare and Labor of JAPAN
(Research on Pathogenesis of Diffuse Parenchymal Lung Diseases)
July 2000 Research on Pulmonary Fibrosis Award (Okamoto Award)
2002 – present Member of a research group of the Ministry of Health, Welfare and Labor of JAPAN
(Strategy for Clinical Research on Treatment of Idiopathic Interstitial Pneumonias)
April 2002 – present Member of the International Committee Meeting of the Japanese Respiratory
Society
August 2002 Award for Research on Diffuse Lung Diseases (from Nippon Medical School)
2004 - Associate professor of Pulmonary medicine, Nippon medical School
2008 - Visiting Professor of Tongji University, School of Medicien (Shanghai)
2008.10 - **Professor of Graduate School of Medicine, Department of Pulmonary, Infection
and Oncology in Nippon Medical School**
2010 to 2012 National Delegate of ERS-Japan
2010. 4- Director of Asian Pacific Thoracic Academy (APTA)
2011. 1- WASOG vice president
2011. 3- Global Steering Committee member for INPULSIS trial
2011. 6- **PMDA** committee member for survey of adverse drug reaction
2013. 4 - Visiting Professor of National **University of Mie**
2013. 4- **Associate Editor of Respirology Case Reports Journal**
2013. 12 - Part-time Assistant Professor of National **University of Kyoto**
2014. 10- WASOG president elect
2016. 4- **Research Associate** of National University of Mie
2016. 5- Visiting Professor of **Nevada University**
2016. 6- Auditor of **Japanese Respiratory Foundation**
2017. **WASOG Board of Director**

Research Activities

- Interests: 1) Diffuse lung diseases (pathogenesis of interstitial pneumonia, relationships to environmental factors and occupation, genetic predisposition to diffuse panbronchiolitis, pathogenesis of sarcoidosis, pulmonary proteinosis, hypersensitivity pneumonitis, etc.). 2) novel effects of macrolide derivatives (non-antibiotic anti-inflammatory effects)
- Institutional organizer for clinical trials of new compounds for IPF:
 - 1) neutrophil elastase inhibitor (ONO-5046),
 - 2) lecithinized-SOD (PC-01C),
 - 3) anti-fibrotic agent (Pirfenidone); Phase-2, Phase-3 organization. (Japan Trials)
- International Steering Committee Member of **Nintedanib** (BIBF1120) for IPF, Phase-3 trial (from 2010.12 – 2014.10)
- International Advisory Board Member of **Nintedanib** (BIBF1120) for IPF (from 2014.10 -)
- International drug-safety monitoring board (**DSMB**) member of **Tofacitinib** (CP690,550, old name; Tasocitinib) for Rheumatoid Arthritis, 2010 – 2015.
- PMX-DHP(direct hemoperfusion) for Acute Exacerbation of IPF. Organizer in Ministry of Health, Labor and Welfare (MHLW) of Japan. 2008 – 20xx.
- Novel Action of Macrolide Research Group, Organizer. 1994 – 20xx.
- Post Marketing Surveillance of pirfenidone in Japan, Advisory Board Member. 2009 – 20xx.
- A Member of Review Board of Drug related adverse events and New Drug Evaluation, in **PMDA** (Pharmaceuticals and Medical Devices Agency; <http://www.pmda.go.jp/>). 2011-20xx.
- Chief Investigator of **PC-SOD** (LTT Bio) for IPF, Cooperative Clinical Trial (Japan and Korea) (from 2010.10)
- PASSPORT (post-authorization safety registry of pirfenidone in EU) Advisory Board Member (2013.12-)
- GSK new drug development Advisory Board Member (2015, March-)
- Steering Committee Member of SSc-ILD Trial with Nintedanib (1199.247) (2016.10-)

- **Publications:**

J Exp Med 170: 1445, 1989;
● **Cancer Res** 52: 1490, 1992;
Cancer Immunol Immunother 38: 294, 1994;
Scand J Immunol 42: 202, 1995;
Clin Infect Dis 23: 1325, 1996;
● **Thorax** 53: 186, 1998;
● **Am J Respir Crit Care Med** 157: 1829, 1998;
● **Am J Respir Crit Care Med** 158: 846, 1998;
J Neurol Neurosurg Psychiatry 66(1): 97, 1999;
Tissue Antigens 53: 366, 1999;
J. Hum Genet 44(2): 164, 1999;
Respir Med 93: 752, 1999;

Thorax 55: 147, 2000;
●**Am J Hum Genet** 66: 501, 2000;
J Clin Immunol 120: 356, 2000;
●**Am J Respir Crit Care Med** 162: 658, 2000;
Jpn J Int Med 39 : 970, 2000;
Sarcoidosis Vasculitis and Diffuse Lung Disease 17: 256, 2000;
●**Thorax** 55: 755, 2000;

J Hum Genet 46: 96, 2001;
Sarcoidosis Vasculitis and Diffuse Lung Disease 18: 312, 2001;
Chest 120S: 20, 2001;
Chest 120S: 71, 2001;
British J Dermatol 145: 123, 2001;
●**Eur Respir J** 18: 515, 2001;
●**Eur Respir J** 18: 753, 2001;
Recent Res Developments in Respir & Crit Care Med. 1: 191, 2001;
Bronchol Bronchoesophagology, 107, 2001;

Experimental Lung Research, 28: 201-217, 2002;
Macrolide Antibiotics, ed. by S Omura, **Academic Press**:533, 2002;
Experimental Lung Research 28: 493, 2002;
Chest 122: 2137-2145, 2002;
Cellular Immunol 219: 73-81, 2002;

Chest 123: 2007-2011, 2003;
Respirology 8: 316-320, 2003;
Experimental Lung Research 29: 607-622, 2003;

●**Genomics** 84: 613-622, 2004;
Annals of Nutrition and Metabolism 48(6): 390-397, 2004;

●**Am J Respir Cell Mol Biol** 32(2): 93-98, 2005;
Annals of Occupational Hygiene 49(3): 259-265, 2005;
●**Am J Respir Crit Care Med** 171: 949-957, 2005;
●**Am J Respir Crit Care Med** 171: 1040-1047, 2005;
Internal Medicine 44(3): 167-168, 2005;
Internal Medicine 44(6): 529-530, 2005;
Modern Rheumatol 15(3): 173-179, 2005;
Experimental Lung Research 31(4): 405-415, 2005;
Respirology 10(4): 504-509, 2005;

●**Respir Res**, 7(1): 16, 2006;
Int J Tuberc Lung Dis 10(3): 333-339, 2006;
Clin Immunol 121(2): 227-235, 2006;
Internal Medicine, 45(18): 1033-1038, 2006;
●**Respirology** 11: 249-261, 2006; (Review)

Jpn Medical Association Journal (JMAJ) 50(6): 405-411, 2007; (Review)
J Infect Chemother 13(5): 343-345, 2007;
Internal Medicine 46 (20): 1739-1744, 2007;
J Med Microb 56:305-12, 2007;
Exp Lung Res, 33: 227-244, 2007;

Inter Med 47(1): 15-20, 2008;
Eur Respir J 31(2): 372-379, 2008;
J Am Geriatr Soc 56: 1358-1360 2008;
Exp Lung Res 34(3): 125-139, 2008;
Inter Med 47(7): 585-591, 2008;
J Nippon Med School 75(2): 96-105, 2008;
Experimental Lung Research 34: 343-354, 2008;
 • **Am J Respir Crit Care Med** 177: 1397-1398, 2008. (Letter)
Clinical Immunology 128: 366-373, 2008.
Immunopharmacology and Immunotoxicology 12: 1-15, 2008.
Intern Med 47(16): 1465-1472, 2008.
Respir Med CME Vol 1/ Issue 2: p75-81, 2008; (Review)

Int J Med Sci. 6(1): 1–8, 2009.
Intern Med 48(9): 665-672, 2009.
Chinese J Practical Int Med 29(10): 903-905, 2009.; Macrolide for Common Diseases (Review)

Respirology 15: 126-131, 2010;
Pharmacology. 85(1): 41-47, 2010;
Diagnostic Microbiology and Infectious Disease. 66: 253-60, 2010;
 • **Eur Respir J** 35: 821-829, 2010; pirfenidone phase III
Am J Physiol-Lung Cellular and Molecular Physiology 298(3): L348-360, 2010; PC-SOD inhalation
Blood Purification 29(4):1-6, 2010.; PMX-DHP
Intensive Care Med. 36(5): 906-907, 2010.; H1N12009
Cell Death and Differ. 17: 1882-1895, 2010.; Leflunomide for EMT
Lung Cancer. 2010 May 19. Carbo+Pacri
 • **Biochem Pharmacol.** 80(6): 920-31, 2010.; HSP70 for fibrosis
Clinical Immunol 137(2): 234-41, 2010.; Nrf2 against DEP inflammation
 • **Expert Review of Respiratory Medicine** 4(3): 301-310, 2010. Pirfenidone in IPF (Review)

Human Genetics 129: 117-128, 2011. DPB gene
Pharmacology. 87: 204-13, 2011.; Zartoprofen
J Thorac Oncol. 6(4): 801-7, 2011.; Carbo+Etopo
J Pharma Exp Ther, 338(3): 810-8, 2011. PC-SOD for emphysema
 • **Respiratory Research** 12: 93, 2011.; 5% change of % VC
Blood Purification 32(4):310-316, 2011.; HMGB1 in PMX-DHP
Public Library of Science (PLoS) One 6(11): e27296, 2011.; HSP70 inhibition by gefitinib
Current Opinion in Pulmonary Medicine 17(5): 303-307, 2011.; Sarcoidosis vs IPF (Review)
 • **Respiratory Research,** 12:143, 2011.; pirfenidone phase III sub analysis >70% of VC

• **Respirology,** 17(3):467-77, 2012. NAC for IPF
Intern Med. 51(3):271-6, 2012.; DPB in China
Chest Mar 29, 2012.; pirfenidone + PC-SOD
Am J Physiol - Lung Cellular Mol Physiol, 2012.; IgM type for GM-CSF in PAP
Am J Physiol - Lung Cellular Mol Physiol, 302: L1250-L1261, 2012 ; PC-SOD COPD mice, pulmonary function
 • **Intern Med.** 51(12): 1487-91, 2012.; Retrospective analysis in PMX-DHP for AE of IPF.
Sarcoidosis Vasculitis and Diffuse Lung Diseases 29: 19-25, 2012.; DPB prevalence in Japan
Biochem Biophys Res Commun. 424(1):112-7, 2012.; Fut8 in COPD
Eur Respir J 40: 485-494, 2012. ML for COPD exacerbation (Review)
 • **Therapeutic Advance in Respiratory Diseases** 6(2): 107-114, 2012.; pirfenidone (Review)
Am J Respir Crit Care Med 2012.;(Letter to the Edit.) for ACE-IPF
Respirology 2012. ; (Reply to Letter) (in press) PCP in non-HIV

APSR Respiriology UPDATES; 4(11): APSR Education Publication, 2012. IPF trial endpoint, Sarcoidosis.

Intern Med. 51(13):1689-94, 2012. Sarcoidosis in Upper GI.

Intern Med 51(13): 3085-8, 2012. CA-MRSA in H1N19002 flu.

Pulm Pharmacol Ther. 2013. EM703 inhibit NF-kB.

Intern Med 52: 263-267, 2013. IP in Eberolimus therapy.

Pulm Pharmacol Ther. 26 : 318-324, 2013. EM703, inhibition of NF-kB.

●**Sarcoidosis Vasc Diffuse Lung Dis. 30(1):73-7, 2013.; SP-C mutation (Y104H)**

Respir Invest, 51(4): 257-9, 2013. ML for 2009H1N1.

Community Acquir Infect 2014;1:6-10. Macrolide antibiotics: 25y of use and future treat. (Review)

●**Respir Res, 2014. Feb 8;15:16. doi: pirfenidone inhibits fibrocyte.**

●**New Engl J Med 2014 May 18. INPULSIS trial(1199.32, 1199.34).**

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27. Organ Assessment of Sarcoidosis.

●**J Pharmacol Exp Ther. 2014 Apr 25. Mepenzolate ameliorates fibrosis.**

●**Pulmonary Medicine 2014, 14:86. PC-SOD inhibits SP-A in div trial.**

Pulmonary Medicine 2014, 14(1):104. CPFE: correlation with pathology.

●**Sarcoidosis Vasculitis and Diffuse Lung Dis. 2014; 31: 235-238. Pirfenidone inhibits SSc-ILD.**
Miura Y

●**Eur Respir J 2014. Pirfenidone and Nintedanib. Ogura T**

●**Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-e19. EB guideline.**

●**World J Respirol 2015 March 28; 5(1): 4-16. Sarcoidosis, Inomata M.**

●**Expert Opinion on Orphan Drug. 3(5): 587-597, 2015. Pirfenidone, Miura.**

Pulm Pharmacol Ther. 2015 Jun;32:29-36. SP-D Nintedanib, Kamio K.

Clin Respir J. 2015 Feb 17. Ig for IPF, Enomoto N.

Sarcoidosis Vasculitis and Diffuse Lung Disease 31: 325-335, 2015. Mochimaru, H.

Respir Investig. 53(2):51-9, 2015. National Registry of IPF. Bando M.

Sarcoidosis Vasc Diffuse Lung Dis. 2015. Sarcoidosis in Kidney. Kamata,

Respir Investig. 2015 Nov;53(6):271-8. Kondoh Y, risk for AE-IPF.

Respir Investig. 2015 Nov;53(6):279-87. Taguchi Y, extended analysis of phase III of PFD for IPF.

Respir Investig. 2015 Nov;53(6):288-95. Miyazaki Y, CyA for severe IPF.

Core Evid. 2015 Aug 27;10:89-98. Inomata M, Nintedanib Review

●**Am J Respir Crit Care Med, 2016. Costabel U, INPULSIS sub analysis.:**

Hum Pathol. 2016 May;51:57-63. Kokuho N, Pulm Lymphoma in Sarcoidosis.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 29;11:649-55. Kubota Y, Left ventricular dysfunction in COPD

Intern Med. 2016. 55(5):443-8. Bando Y, Long term use of PFD.

Respirology. 2016 Jul 11. doi: 10.1111/resp.12852. Taniguchi Y, Asian Sub analysis of INPULSIS.

J Allergy Clin Immunol. 2016 Jul;138(1):281-283. Yatagai Y, HCG22 gene for Asthma.

●**Respir Res. 2016 Jul 22;17(1):90. Iwata T, PFD for surgery induced AE-IPF.**

Respirology. 2016 Sep 11. doi: Azuma A, Japanese Sub Analysis of INPULSIS.

Respir Investig. 2017 Jan; 55(1) 1. Azuma A, Editorial. Safety management of Nintedanib for IPF.

Pulm Pharmacol Ther. 2017 Mar 14. pii: S1094-5539(16)30204-8, Kamio K, Azuma A, XPLN is modulated by HDAC inhibitors, SPARC.

Int J Mol Sci. 2017 Mar 17;18(3). pii: E649. Li YJ, Azuma A, Nrf2_Diesel Exhaust Inhalation

Grants

- April 1995 – March 1996 Grant for Scientific Research from the Ministry of Education – General Research (C)
Subject: Basic research on antibody therapy against lung cancer cells using a humanized chimera antibody
- April 1998 – March 2000 Co-investigator, Grant for MHW Priority Scientific Study Group; Principal Investigator, Shoji Kudoh
Subject: Development of cellular/molecular pathology-specific treatment of idiopathic interstitial pneumonia
- April 1998 – present Co-investigator, Study on Health Effects of Pollution, funded by the Ministry of the Environment
Subject: Experimental study of effects of airborne particulates on the respiratory system
- July 25, 2000 Awarded Okamoto Toshi Research Grant for Pulmonary Fibrosis in 2000 by Toyo Trust Bank
Subject: Study of inhibition of bleomycin-induced pulmonary fibrosis by macrolides
- 2000-2001 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2)
Subject: Basic therapeutic research on inhibition of endothelial cell adhesion and tissue invasion in interstitial pneumonia.
- 2002-2004 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2), (14570569)
Subject: Study of the mechanism of intracellular inhibitory effects of interferons γ and β in interstitial pneumonia and pulmonary fibrosis.
- 2002-2003 Co-investigator, Grant for Scientific Research from the Ministry of Education – Exploratory Research
Subject: Study of effects of exposure to diesel exhaust on tuberculosis infection
- August 7, 2002 The 70th Scholarship from Nippon Medical School
Subject: Clarification of etiology and pathology of diffuse lung disease and development of methods of treatment of it
- 2002 – 2004 Co-investigator, Scientific research grant from the MHLW
MHLW Priority Disease Study Group on Diffuse Lung Disease (Director:

Toshihiro Nukiwa)

- April 1998 – present Co-investigator, Study on health effects of pollutants, funded by the Ministry of Environment
Subject: Experimental research on effects of airborne particles on the respiratory system
- 2003-2005 Co-investigator, Grant for scientific research from the MHLW
Research project to overcome intractable diseases (Director; Shoji Kudoh)
Subject: Clinical research on breakthrough treatment for idiopathic interstitial pneumonia (15180401)
- 2005-2007 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2), (17590806)
Subject: Basic research on drug-induced acute lung injury and its mechanism of action in Japanese.
- 2011-2013 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2), (23591163)
Subject: Basic research on bonemarrow derived progenitor cell in fibrosis and research on efficacy evaluation of novel agents.
- December 2004 **Award for Best Presentation.** 9th Asian Pacific Society of Respirology (APSR)
Subject: EM703 - New Derivative of Erythromycin: Improvement of Pulmonary Fibrosis in Bleomycin-Challenged Mice by Regulation of Smad 3 Messenger RNA Expression.
- November 24, 2005 **Awarded** Suzuki Kenzo Research Grant in 2005 by Toyo Trust Bank
- August 22, 2006 **Awarded** Imai Kenzo Research Grant for Sarcoidosis in 2006 by Toyo Trust Bank. Subject: Development of high sensitive assay method of ERISPOT for diagnosis of Sarcoidosis.
- November 24, 2006 Asian Pacific Society of Respirology (APSR), Education Committee Member.
- September 1, 2015 Assembly **Head Elect of ILD** in APSR
- November 1, 2017 Assembly **Head of ILD** in APSR

Invited Lecture:

1. Lecture for certified physicians and specialists: “A comparison of bronchoscopic biopsy and thoracoscopic biopsy in patients with diffuse lung disease”. Kanto District Meeting of the Japan Society for Respiratory Endoscopy, 1999.2.
2. **Invited Lecture:** “Idiopathic interstitial pneumonia”. 20th Annual Meeting of Japanese Inflammation Society, 2000.7.
3. **Luncheon Seminar:** “Aspects for treatment of idiopathic interstitial pneumonia”. 26th Annual Meeting of Japanese Bronchology Society (Tokyo, Nagata), 2003.5.
4. **Invited Lecture** at Nebraska Medical Center: “**New Concept of Strategy for Treatment in Patients with Idiopathic Pulmonary Fibrosis**”. (Nebraska Medical Center, USA), 2005.9.14.
5. **Invited Lecture in Postgraduate Course of Chinese Respiratory Society.** “**Pathogenesis and new Treatment in Patients with Idiopathic Pulmonary Fibrosis**”. (Organizer: Yuan-jue Zhu, Peking Union Hospital, Beijing, China), 2005.11.13.
6. **Invited Lecture, Meet the Professor Seminar** “**New Application of Anti-inflammatory Action of Macrolide**” (American Thoracic Society Annual Meeting 2007 in San Francisco), 2007.5.22.
7. **Invited Lecture** “**Ethnic difference of acute exacerbation of IPF**” (9th World Association of Sarcoidosis and Other Granulomatous Disorders Meeting 2008 in Athens, Greece), 2008.6.21.
8. **Invited Lecture** “**EM703 a New Derivative of Erythromycin, Inhibits Lung Fibrosis Induced by TGF- β Signaling in Murine and Human Lung Fibroblasts**” **EHRlich II 2nd World Conference on Magic Bullets** 2008 in Nürnberg, (Germany), 2008.10.3-5.
9. **Invited Lecture** “**The Treatment of Idiopathic Pulmonary Fibrosis with Pirfenidone**” **5th WASOG and Interstitial Lung Disease Meeting** at Charleston, South Carolina, 2009.3.25-27.
10. **Invited Lecture** “**Ethnic Difference of Acute Deterioration and Treatment Hopes of IPF**” at Keck School of Medicine, University of Southern California (USC), 2010.5.14.
11. **Invited Lecture** “**Expected Aspects of Macrolide for Amelioration of Severity of A/H1N1 flu 2009**” at the prof. Rubin Research Presentation Meeting in Virginia Commonwealth University (VCU), Dept. of Pediatrics, 2010.11.12.
12. **Invited Lecture** “**Impact of Clinical Studies on Treatment; Treatment of IPF with pirfenidone in Japan**” *Advancing in IPF Research (AIR)*, in Rome, Italy. November 30 – December 1, 2012.

13. **Invited Lecture PIPKRA Indonesia Respiratory Society** 14:00 – 14:30; 2014.2.13-14
 1. *Plenary symposia 4(PS4)* (attended by 700-1000 Medical doctors): “*Idiopathic Pulmonary Fibrosis: Current Diagnosis and Management of the Difficult Disease*” 14:30 – 14:50
 2. *Satellite symposia 13(SS13)*: (attended by around 300 Medical Doctors) “*Idiopathic interstitial pneumonia: diagnosis and treatment approach*”
14. 2015.6.5 Friday; **WASOG 2015**, Satellite Symposium, “Experience of PFD Treatment with IPF, Jap and Eur” Chairing by Carlos AC Pereira, Sao Paulo, Brazil.
15. **REG Asia Pacific Summit 2015** in Singapore. ‘*The gap between RCT Management of Real-world clinical setting in rare lung diseases (IPF / ILD)*’ 2015.4.25
16. **AFT Meeting** in Singapore. [pirfenidone PMS meeting]
2 lectures at Family Physician and Singapore Thoracic Society Expert Meeting, 2015.3.25
17. **GSK Advisory Board Meeting** (London) ‘Pirfenidone in a real world setting: Japanese experience in clinical practice’, 2015.3.22
18. **Invited Seminar** of Respiratory Medicine in University of Nevada School of Medicine, “Practical Management of Diffuse Parenchymal Lung Diseases based on the Evidence-based Medicine” 18 May, 2016.
19. **Invited Lecture** “Occupational Interstitial Lung Diseases”, **8th WASOG ILD Congress** at Gdansk, Poland. Conference Chair; prof. Chair by Anna Dubaniewicz, Gdansk University.; 3 June, 2016.
20. **Invited Lectures** at PIPKRA in Jakarta (**PIPKRA Indonesia University Respiratory Society**), **PG course 1** “Idiopathic Pulmonary Fibrosis: Diagnostic Approach”, **PG Course 2** “Idiopathic Pulmonary Fibrosis: Advanced Therapeutic Approach”, **Luncheon Symposium: Diffuse Lung Disease** “Novel Pathogenesis and Treatment of IPF”; 16-18 Feb, 2017.

Certifications/Qualifications

Secretariat, MHLW Priority Disease Study Group on Diffuse Lung Disease
 Member of MHLW Priority Study Group on "Development of cellular/molecular pathology-specific treatment of idiopathic interstitial pneumonia"
 Member of Study Group of the Ministry of Environment on Effects of Air Pollutants in Humans
 Member of Study Group on Intractable Disease of the Bureau of Public Health, Tokyo Metropolitan Government
 Councilor of the Japan Society of Sarcoidosis and other Granulomatous Disorders
 Manager of the Study Group on Diffuse Lung Disease
 Secretary General and Committee Member of the Research Group for Novel Effects of Macrolides

Editor of "Respiratory Molecular Medicine" Journal
Editor of the book "Inflammation, Immunity and Macrolides"
Local Medical Expert on Occupational Accidents, Tokyo Labor Bureau, MHLW
Member of the Committee for Specification of Sufferers from Air Pollution in Adachi Ward, Tokyo
Representative of the Japanese Respiratory Society (from April 2004)
Executive Committee Member of World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) (from January 2005)
ATS International Conference Committee Member 2005-2006
Member of the Certification Examination Development Committee of the Japanese Respiratory Society (from January 2005)
External member of the Committee for Investigation of the Safety of Medical Practice in Toranomon Hospital (from September 2005)
Associate Professor of Nippon Medical School (from October 2005)
Professor of Graduate School of Medicine, Nippon Medical School (from October 2008)

Editorial Board Member of **Respirology (2008 -)**
International Editorial Board of PNEUMON (GREEK) (from January 2007)
ATS International Lung Health Committee Member (2007 – 2009)
Editorial Board Member of **Pulmonary Medicine (2009 -)**
National Delegate of ERS-Japan (2009 - 2012)
Drug Adverse Reaction Research Committee Member in PMDA (from 2011.6)
Vice President of World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) (from January 2011)
ATS document development and implementation committee (DDIC) member for IPF guideline (from 2012.5.20)

Visiting Professor of Mie University (from April 2013)
Associate Editor of Respirology Case Reports Journal (from April 2013)
Organize Committee member of WASOG_ Parenchymal Lung Disease (June 2013, Paris)
Part-time Assistant Professor in Kyoto University (from December, 2013)
President Elect of WASOG (October, 2014)
Associate Editor of Respiratory Investigation (from April, 2014)
Research Associate of Graduate School in Mie University (from May, 2016)
Visiting Professor of Nevada University (from June, 2016)